Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $990.39 million. The enterprise value is $967.09 million.
Important Dates
The next estimated earnings date is Tuesday, March 25, 2025, before market open.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 85.82 million shares outstanding. The number of shares has increased by 28.56% in one year.
| Current Share Class | 85.82M |
| Shares Outstanding | 85.82M |
| Shares Change (YoY) | +28.56% |
| Shares Change (QoQ) | -1.62% |
| Owned by Insiders (%) | 6.65% |
| Owned by Institutions (%) | 2.13% |
| Float | 16.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.98 |
| Forward PS | n/a |
| PB Ratio | 15.67 |
| P/TBV Ratio | 16.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 399.83 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.21 |
| EV / EBITDA | 81.94 |
| EV / EBIT | 93.20 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.72, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.72 |
| Quick Ratio | 3.11 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.32% and return on invested capital (ROIC) is 6.54%.
| Return on Equity (ROE) | -85.32% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 6.54% |
| Return on Capital Employed (ROCE) | 9.39% |
| Revenue Per Employee | $177,121 |
| Profits Per Employee | -$149,784 |
| Employee Count | 593 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GYRE has paid $5.82 million in taxes.
| Income Tax | 5.82M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.78% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -23.78% |
| 50-Day Moving Average | 11.29 |
| 200-Day Moving Average | 12.47 |
| Relative Strength Index (RSI) | 47.99 |
| Average Volume (20 Days) | 53,523 |
Short Selling Information
The latest short interest is 1.25 million, so 1.45% of the outstanding shares have been sold short.
| Short Interest | 1.25M |
| Short Previous Month | 1.26M |
| Short % of Shares Out | 1.45% |
| Short % of Float | 7.75% |
| Short Ratio (days to cover) | 12.46 |
Income Statement
In the last 12 months, GYRE had revenue of $105.03 million and -$88.82 million in losses. Loss per share was -$1.17.
| Revenue | 105.03M |
| Gross Profit | 101.08M |
| Operating Income | 10.38M |
| Pretax Income | -74.61M |
| Net Income | -88.82M |
| EBITDA | 11.80M |
| EBIT | 10.38M |
| Loss Per Share | -$1.17 |
Full Income StatementBalance Sheet
The company has $25.09 million in cash and $1.80 million in debt, giving a net cash position of $23.30 million or $0.27 per share.
| Cash & Cash Equivalents | 25.09M |
| Total Debt | 1.80M |
| Net Cash | 23.30M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 98.47M |
| Book Value Per Share | 0.74 |
| Working Capital | 40.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $2.48 million and capital expenditures -$4.70 million, giving a free cash flow of -$2.23 million.
| Operating Cash Flow | 2.48M |
| Capital Expenditures | -4.70M |
| Free Cash Flow | -2.23M |
| FCF Per Share | -$0.03 |
Full Cash Flow StatementMargins
Gross margin is 96.23%, with operating and profit margins of 9.88% and -84.57%.
| Gross Margin | 96.23% |
| Operating Margin | 9.88% |
| Pretax Margin | -74.10% |
| Profit Margin | -84.57% |
| EBITDA Margin | 11.24% |
| EBIT Margin | 9.88% |
| FCF Margin | n/a |